The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01B | Antimetabolites | |
| 4 | L01BC | Pyrimidine analogues | |
| 5 | L01BC07 | Azacitidine |
| Active Ingredient | Description | |
|---|---|---|
| Azacitidine |
Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ONUREG Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VIDAZA Powder for suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
